At a Rheumatology Research Institute that carries his name, the scientific director of the eponymous institute spoke with socialbites.ca about Evgeniy Nasonov’s efforts to develop a technology aimed at personalizing arthritis treatment. Nasonov is a prominent medical leader, serving as President of the All-Russian public organization “Russian Association of Rheumatologists,” a member of the Russian Academy of Sciences, and a professor with a long-standing reputation in rheumatology.
“Personalized therapy matters a great deal to us. There are many medicines available, yet treatment decisions are often made empirically. We have a grasp of the general patterns that drive inflammation, but the way these pathways unfold can vary from patient to patient. We do not always know the exact drug that will work best for a given individual,” the academician noted.
According to Nasonov, the proposed technology would fuse clinical expertise with molecular biology research, specifically by analyzing a patient’s DNA. He described the project as a study on the polymorphism of genes that regulate pro-inflammatory mediators. The goal is to predict how a particular medication might perform in a given case based on the genetic and molecular data gathered. He added that such approaches are pursued worldwide, yet there has not yet been a breakthrough that translates these insights into routine clinical practice.
Further exploration of arthritis treatments is available, with Nasonov’s insights featured in socialbites.ca reports. The Institute continues to examine a range of innovative strategies for managing inflammatory joint disease as part of its broader research agenda.
Earlier, the academician highlighted that Russia is advancing a cellular method for treating arthritis, underscoring a commitment to expanding the arsenal of therapeutic options for patients.